Finance

Lists
IMCR:NASDAQ
Immunocore Holdings PLC - ADR
$30.85
+0.69%
(+0.21) 1D
$30.85
0.00% (0.00)
After hours
Closed: Sep 29, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMCR...
Open
$30.78
High
$30.93
Low
$30.27
Mkt. cap
1.61B
Avg. vol.
378.55K
Volume
0.00
52-wk high
$40.71
52-wk low
$27.56
EPS
-$0.37
Beta
0.74
Shares outstanding
51.50M
No. of employees
524
Open
$30.78
High
$30.93
Low
$30.27
Mkt. cap
1.61B
Avg. vol.
378.55K
Volume
0.00
52-wk high
$40.71
52-wk low
$27.56
EPS
-$0.37
Beta
0.74
Shares outstanding
51.50M
No. of employees
524
Profile
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
About Immunocore Holdings PLC - ADR
CEOBahija Jallal
Employees524
Founded2008
Headquarters-
SectorBiotechnology
Websiteimmunocore.com
Analyst ratings
Based on 6 analysts giving stock ratings to IMCR in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for IMCR in the last 3 months.
Highest
Current $30.85
$100.00 (+224.15%)
Average
$62.83 (+103.66%)
Lowest
$35.00 (+13.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
$100.00
+224.1%
09/21/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
$50.00
+62.1%
08/21/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
$43.00
+39.4%
08/07/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
$74.00
+139.9%
08/06/2026
Graig Suvannavejh
Mizuho Securities
Hold
Maintained
$35.00
+13.5%
08/07/2026
Gil Blum
Needham
Buy
Maintained
$75.00
+143.1%
08/06/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
05/06/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$60.00
+94.5%
05/06/2026
Jeff Jones
Oppenheimer
Buy
Maintained
$86.00
+178.8%
04/20/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
$60.00
+94.5%
04/14/2026
Faisal Khurshid
Jefferies
Hold
Downgraded
$33.00
+7%
03/15/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.02 / $0.02
-215.81%miss
Revenue / Est. (USD)
115.93M / 110.92M
+4.51%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
103.69M
104.48M
106.68M
115.93M
Cost of goods sold
71.08M
81.52M
434.00K
75.03M
Cost of revenue
71.08M
81.52M
434.00K
75.03M
Research and development expenses
-
-
61.11M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39.78M
42.64M
37.85M
43.89M
Operating expense
39.78M
22.92M
98.96M
43.89M
Total operating expenses
110.86M
104.44M
99.40M
118.92M
Operating income
-7.17M
37.00K
7.28M
-3.00M
Other non operating income
5.06M
-15.22M
-
-
EBT including unusual items
304.00K
-15.79M
13.27M
-514.00K
EBT excluding unusual items
304.00K
-15.79M
11.50M
-3.58M
Income tax expense
481.00K
14.27M
301.00K
294.00K
Effective tax rate
158.22%
-90.33%
2.27%
-57.20%
Other operating expenses
-
-19.73M
-
-
Net income
-177.00K
-30.06M
12.97M
-808.00K
Net profit margin
-0.17%
-28.77%
12.16%
-0.70%
Earnings per share
-
-0.60
0.25
-0.02
Interest and investment income
4.12M
3.91M
3.42M
3.58M
Interest expense
-3.04M
-3.05M
-3.05M
-3.06M
Net interest expenses
1.08M
853.00K
367.00K
520.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.37M
871.00K
8.23M
-1.97M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps